Essential Updates for PsA: A Complex Disease to Manage

Program Overview

PsA: Highly Heterogeneous Disease

Epidemiology of PsA

Pathogenesis of PsA

Immunopathogenesis of PsA

Main Players in IL-23/IL-17 Axis: Roles in Psoriasis and PsA

PsA: Importance of Early Diagnosis

Delayed Diagnosis of PsA Is Associated With Worse Long-Term Outcomes

Multidisciplinary Management of Patients With PsA

PsA Management: Bridging Rheumatology and Dermatology

PsA Treatment

PsA Principles of Treatment

Patient Concerns Are Important

The Psychosocial Burden of PsA

Outcome Measures in PsA*

Using Outcome Measures in the Management of Patients With PsA

Treat-To-Target

Early Intervention and Tight Control of Inflammation in Patients With PsA: TICOPA

TICOPA: ACR20 Response at 48 Weeks

TICOPA: Commonly Reported AEs

MDA Criteria for PsA

Targeted Agents for the Treatment of PsA

Novel Targeted Therapies for the Treatment of PsA

IL-17 Isoforms, Their Receptors, and Key Molecules Involved in Signal Transduction

Treatment With IL-17 Inhibitors in Patients With PsA

Ixekizumab Improves PROs in bDMARD-Naive Patients With PsA: Results From SPIRIT-P1

Bimekizumab in PsA: Results From BE ACTIVE Phase 2b Study

Safety Profile of IL-17 Inhibitors in PsA

Use of IL-17 Inhibitors in Clinical Practice

The Psychosocial Burden of PsA and the Importance of PROs

Program Summary

Program Summary (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)